Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Neoplastic tissue" patented technology

Neoplastic, adj. (1) An abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of normal tissue, and persists in the same excessive manner after cessation of the stimuli evoking the change. (2) Any autonomous proliferation of cells, benign or malignant.

Neutron beam dynamic regulation and control method and system in BNCT process

The invention discloses a neutron beam dynamic regulation and control method and system in a BNCT process, and the method comprises the following steps: constructing a neutron beam-out regulation and control model, and obtaining a mapping relation between the intensity of a neutron beam and a neutron dose rate; dynamically monitoring the boron concentration of the tumor tissue and the boron concentration of the normal tissue to obtain a real-time T / N value; converting the T / N value into neutron beam intensity in real time, and substituting the neutron beam intensity into the neutron beam output regulation and control model to obtain a real-time neutron dose rate; comparing the obtained real-time neutron dose rate with a preset neutron dose rate, and if there is a difference between the real-time neutron dose rate and the preset neutron dose rate, adjusting neutron source parameters until the real-time neutron dose rate is consistent with the preset neutron dose rate; and the step S2 to the step S4 are repeated, and neutron beam dynamic regulation and control in the BNCT process are achieved. According to the invention, the technical problem that the neutron outgoing beam regulation and control precision and efficiency are low due to the fact that the real-time change of the boron concentration is not considered in the prior art can be solved.
Owner:NEUTRON TIMES (QINGDAO) INNOVATION TECH CO LTD +1

Chimeric protein toxins for expression by therapeutic bacteria

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.
Owner:BERMUDES DAVID

Method and device for examining fluorescence image of mammalian tissue and medical treatment device

Disclosed herein is an improved examination method for examining a fluorescence image taken of mammalian tissue treated with a fluorescent agent to be photosensitive and irradiated with excitation light, the fluorescence image (FI) comprising an array of pixels having respective fluorescence signal values, the fluorescence signal values include fluorescence signal values representing a first quantity (N1) of mammalian tissue in the fluorescence image. The improved inspection method comprises: determining (S6) a reference value (IR) such that a second number (N2) of fluorescence signal values contained in a first number of fluorescence signal values is less than or equal to said reference value and the remainder of the first number of fluorescence signal values exceeds said reference value, said second number being a predetermined fraction of said first number; determining (S7) an average fluorescence signal value ([mu] R) and a standard deviation ([sigma] R) of fluorescence signal values contained in the second number of fluorescence signal values; performing (S8) image segmentation in the fluorescence image (FI) to distinguish between a target region (TR) representing a portion identified as tumor tissue in the mammalian tissue (MT) and a reference region (RR) representing a remaining portion in the mammalian tissue (MT), including a determination for each pixel (p) and a determination for each pixel (p); determining that the pixel belongs to the target region (TR) if the signal-to-noise ratio CNR (p) of the pixel exceeds a predetermined threshold value (TCNR), otherwise determining that the pixel belongs to the reference region (RR), where the signal-to-noise ratio CNR (p) of the pixel is as defined in (I): (I) # imgabs0 # where FI (p) is the fluorescence signal value of the pixel (p), c is a predetermined constant; at least one contour (B) of the target area (TR) is identified (S9).
Owner:UNIVERSITY OF GRONINGEN +1

Model for simulating a brain soft tissue affected by neoplasm and use

PendingUS20260051267A1Educational modelsNeoplastic tissueAnatomy
A model for simulating a brain soft tissue affected by neoplasm has a first portion for simulating a healthy tissue and a second portion for simulating a neoplastic tissue. The first portion and the second portion have a composition including water, gelatin, glycerin and sorbitol. The content by weight of glycerin and sorbitol is predominant over the content by weight of gelatin. The first portion has a liquid dye and the second portion has at least one powdered pigment.
Owner:UPSURGEON SRL

Chimeric protein toxins for expression by therapeutic bacteria

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.
Owner:BERMUDES DAVID GORDON